Health canada grants marketing authorization for trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in people ages 12 and older who have at least one f508del mutation

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced health canada has granted marketing authorization for trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (cf) in people ages 12 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene, the most common cf-causing mutation. with this approval, for the first time, approximately 1,100 eligible p
VRTX Ratings Summary
VRTX Quant Ranking